Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Motesanib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 18/20 | 1.00 |
| ▸ | RET known ✓ | P07949 | 2/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 1.00 |
| ▸ | KIT known ✓ | P10721 | 1/20 | 1.00 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 1.00 |
| ▸ | FLT1 known ✓ | P17948 | 1/20 | 1.00 |
| ▸ | FLT4 known ✓ | P35916 | 1/20 | 1.00 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 1.00 |
| ▸ | RIPK3 | Q9Y572 | 2/20 | 1.00 |
| ▸ | CIT | O14578 | 1/20 | 1.00 |
| ▸ | MAP3K7 | O43318 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | RAF1 | P04049 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | CSF1R | P07333 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Motesanib SCHEMBL29354461 | 1.00 | KDR (1.00) | KDRRETMAP3K20RIPK3CIT | |
| Motesanib SCHEMBL445079 | 0.99 | KDR (0.98) | KDRRETMAP3K20RIPK3CIT | |
| Motesanib SCHEMBL29353301 | 0.97 | KDR (0.95) | KDRRETMAP3K20RIPK3CIT | |
| Motesanib SCHEMBL446673 | 0.97 | KDR (0.95) | KDRRETMAP3K20RIPK3CIT | |
| Motesanib SCHEMBL29361754 | 0.97 | KDR (0.95) | KDRRETMAP3K20RIPK3CIT | |
| SCHEMBL3150119 | 0.92 | KDR (0.85) | KDRRETMAP3K20RIPK3CIT | |
| SCHEMBL4537062 | 0.89 | KDR (0.81) | KDRRETMAP3K20RIPK3CIT | |
| SCHEMBL3144781 | 0.89 | KDR (0.81) | KDRRETMAP3K20RIPK3CIT | |
| SCHEMBL444347 | 0.88 | KDR (0.79) | KDRRETMAP3K20RIPK3CIT | |
| SCHEMBL3155345 | 0.88 | KDR (0.79) | KDRRETMAP3K20RIPK3CIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1267 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4378957-A2 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO PD-1 | Novartis AG (CH) | 2024-06-05 | — | — | EP | claimed |
| CN-115192564-B | Phenylalanine derivative, pharmaceutical composition and application thereof in tumor treatment | 四川大学华西医院 | 2023-11-17 | — | — | CN | claimed |
| CN-115192564-A | Phenylalanine derivative, pharmaceutical composition and application of phenylalanine derivative and pharmaceutical composition in tumor treatment | 四川大学华西医院 | 2022-10-18 | — | — | CN | claimed |
| US-10426779-B2 | Induction of tumor hypoxia for cancer therapy | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2019-10-01 | — | — | US | claimed |
| US-20180050039-A1 | INDUCTION OF TUMOR HYPOXIA FOR CANCER THERAPY | VIRGINIA COMMONWEALTH UNIVERSITY | 2018-02-22 | — | — | US | claimed |
| US-20170224693-A1 | INDUCTION OF TUMOR HYPOXIA FOR CANCER THERAPY | VIRGINIA COMMONWEALTH UNIVERSITY | 2017-08-10 | — | — | US | claimed |
| US-9649316-B2 | Induction of tumor hypoxia for cancer therapy | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2017-05-16 | — | — | US | claimed |
| CN-104043125-A | Induction Of Tumor Hypoxia For Cancer Therapy | UNIV VIRGINIA COMMONWEALTH | 2014-09-17 | — | — | CN | claimed |
| US-20140065139-A1 | Induction of Tumor Hypoxia for Cancer Therapy | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2014-03-06 | — | — | US | claimed |
| US-8648199-B2 | Process for making a solid-state form of AMG 706 | AMGEN INC. (US) | 2014-02-11 | — | — | US | claimed |
| WO-2009126705-A2 | INDUCTION OF TUMOR HYPOXIA FOR CANCER THERAPY | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2009-10-15 | — | — | WO | claimed |
| EP-1915151-A2 | COMBINATIONS FOR THE TREATMENT OF CANCER COMPRISING ANTI-EGFR ANTIBODY AND VEGFR INHIBITORS | Amgen, Inc (US) | 2008-04-30 | — | — | EP | claimed |
| US-20080039501-A1 | Antiangiogenic drug AMG 706 hydrate phosphate salt; AMG 706 is known as motesanib, or N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[(4-pyridinylmethyl)amino]-3-pyridinecarboxamide; oral administration; suspension; cancer | AMGEN INC. (US) | 2008-02-14 | — | — | US | claimed |
| EP-1798230-A1 | Substituted alkylamine derivatives and methods of use | Amgen Inc. (US) | 2007-06-20 | — | — | EP | claimed |
| EP-1358184-B1 | N-(3,3-Dimethylindolin-6-yl){2-[(4-pyridylmethyl)amino}(3-pyridyl)}carboxamide and pharmaceutical compositions thereof. | AMGEN INC (US) | 2007-05-02 | — | — | EP | claimed |
| WO-2006102504-A2 | COMBINATIONS FOR THE TREATMENT OF CANCER COMPRISING ANTI-EGFR ANTIBODY AND VEGFR INHIBITORS | AMGEN INC (US) | 2006-09-28 | — | — | WO | claimed |
| US-20060216288-A1 | Combinations for the treatment of cancer | AMGEN INC (US) | 2006-09-28 | — | — | US | claimed |
| US-20060040956-A1 | Substituted alkylamine derivatives and methods of use | CHEN GUOQING | 2006-02-23 | — | — | US | claimed |
| US-6995162-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2006-02-07 | — | — | US | claimed |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-07-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060216288-A1 | Combinations for the treatment of cancer | TP53, VHL, FOLR2 | KDR 2043/4885RET 925/4885PDGFRB 737/4885 |
| US-20180050039-A1 | INDUCTION OF TUMOR HYPOXIA FOR CANCER THERAPY | HIF1A, HIF1AN, HYOU1 | KDR 953/4885RET 701/4885PDGFRB 1643/4885 |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AADAC, NAT1, PIGO | KDR 13/4885RET 2801/4885PDGFRB 131/4885 |
| US-20140065139-A1 | Induction of Tumor Hypoxia for Cancer Therapy | HIF1A, HIF1AN, HYOU1 | KDR 989/4885RET 711/4885PDGFRB 1585/4885 |
| US-20170224693-A1 | INDUCTION OF TUMOR HYPOXIA FOR CANCER THERAPY | HIF1A, HIF1AN, HYOU1 | KDR 989/4885RET 711/4885PDGFRB 1585/4885 |
| US-10426779-B2 | Induction of tumor hypoxia for cancer therapy | HIF1A, HIF1AN, HYOU1 | KDR 953/4885RET 701/4885PDGFRB 1643/4885 |
| US-20060040956-A1 | Substituted alkylamine derivatives and methods of use | AADAC, NAT1, PIGO | KDR 13/4885RET 2801/4885PDGFRB 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.